Blog

$RAC announces conclusion of an investigator-sponsored trial of bisantrene – Race Oncology

Photo taken from Race Oncology/X

Aug 2, 2024, 00:52

$RAC announces conclusion of an investigator-sponsored trial of bisantrene – Race Oncology

Race Oncology made the following post on X:

“$RAC is pleased to announce the successful conclusion of an investigator-sponsored Phase 1b/2 trial of bisantrene, with trial results showing the drug, in combination with clofarabine and fludarabine, has achieved its primary endpoint for efficacy.
More.”

Source: Race Oncology/X

$RAC bisantrene cancer cancer therapy cancer treatment clinical trial results clofarabine drug efficacy fludarabine Investigator-Sponsored trial OncoDaily Oncology oncology research Phase 1b/2 trial primary endpoint Race Oncology Research successful trial

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage